Mark Frissora
On February 3, 2025 , the Company appointed Mr. Mark Frissora to its Board of Directors.
Highest-materiality recent filing
BioAdaptives' Zeranovia weight loss product shows 5-7 lbs/week loss in dosage trial
Participants lost 5–7 pounds per week in Zeranovia dosage trial.
Mark Frissora, former Chairman/CEO of Hertz and Caesars Entertainment, appointed to Board of Directors on Feb 3, 2025.
BioAdaptives declares one-for-one stock dividend payable in January 2025
One additional common share for each share owned as of the record date.
BioAdaptives gets IRB approval for human trial of weight management product Zeranovia
IRB approved human clinical trial for Zeranovia, a weight management supplement.
BioAdaptives completes 1-for-300 reverse stock split effective Nov 21, 2024
Reverse split reduces outstanding shares from ~1.23B to ~4.1M.
BioAdaptives plans reverse stock split after shares balloon 6,530% in 5 years; CEO cites turnaround
Shares outstanding grew from 18.6M (Jan 2020) to 1.23B (June 2024), a 6,530% increase with no revenue growth.
BioAdaptives appoints James Keener as new CEO and Chairman; Jacobs and Ellis resign
Edward Jacobs resigned as Chairman and CEO; Robert Ellis resigned as director and President, both for personal reasons.
SEC permanently suspended BF Borgers from practicing as accountants and PCAOB auditors on SEC filings, effective May 3, 2024.
On February 3, 2025 , the Company appointed Mr. Mark Frissora to its Board of Directors.
On February 6, 2025, the Company appointed Mr. Reed Harris to its Advisory Board.
Max materiality 0.70 · Median 0.57 · Most common event other_material